The Therapeutic Role of Extracellular Vesicles in COVID-19: Therapeutic and Preventive Mechanism
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Microenvironment".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 9584
Special Issue Editor
Interests: neuroscience; Alzhimer's diseases; Parkinson's diseases; senescence; cell biology; stem cells; extracellular vesicles; biomarker bioinformatics; statistics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Since 2019, SARS-CoV-2 infection and the associated disease COVID-19 has become an urgent global health concern due to the long incubation time and high prevalence. Consequently, many studies are being actively conducted for the rapid and accurate diagnosis and treatment of SARS-CoV-2 infection. Among the numerous methods for the early detection and treatment of this infectious disease, several approaches using extracellular vesicles (EVs) are emerging.
EVs released from various types of cells have been known to participate in several pathological conditions via the delivery of bioactive proteins and lipids, RNA, and microRNA to recipient cells. Regarding SARS-CoV-2 infection, it has recently been reported that EVs derived from mesenchymal stem cells (MSC-EVs) have antiviral activities mediated by miRNA against SARS-CoV-2, and MSC-EVs-based therapies are now being intensively studied for the treatment of COVID-19.
As SARS-CoV-2-infected cells release EVs which might play a role in disease progression, many studies have been conducted to better understand the role of EVs in SARS-CoV-2 infectivity, disease progression, and transmission. Additionally, due to their biocompatibility and functional ability to deliver biomolecules, drugs, and immunological agents to specific cells, EVs have been considered as a new attractive approach for the development of a treatment or vaccine system against COVID-19. However, the mechanisms of the roles of EVs in COVID-19 are only partially understood.
This Special Issue will focus on understanding the cellular and molecular mechanisms responsible for preventive and therapeutic roles of EVs against COVID-19.
We look forward to your contributions.
Dr. Jisook Moon
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- extracellular vesicles
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19)
- EV-associated COVID-19 pathogenesis
- therapeutic intervention
- treatment